{"id":"https://openalex.org/W2575189539","doi":null,"title":"Combination of the vascular disrupting agent DMXAA (AS1404) with bevacizumab and paclitaxel produces synergistic antitumor activity in lung cancer xenografts","display_name":"Combination of the vascular disrupting agent DMXAA (AS1404) with bevacizumab and paclitaxel produces synergistic antitumor activity in lung cancer xenografts","alternate_titles":[],"publication_year":2007,"publication_date":"2007-05-01","ids":{"openalex":"https://openalex.org/W2575189539","mag":"2575189539"},"language":"en","primary_location":{"id":"mag:2575189539","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/67/9_Supplement/4642","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null},"parent_works":[],"lineage":["https://openalex.org/W2575189539"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059069081","display_name":"Hakim Djeha","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Hakim Djeha","raw_affiliation_strings":["Antisoma, Ealing, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antisoma, Ealing, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006654729","display_name":"Kirti Shah","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Kirti Shah","raw_affiliation_strings":["Antisoma, Ealing, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antisoma, Ealing, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089174930","display_name":"Grainne McGeever","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Grainne McGeever","raw_affiliation_strings":["Antisoma, Ealing, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antisoma, Ealing, United Kingdom","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5080549837","display_name":"Donna Dobinson","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Donna Dobinson","raw_affiliation_strings":["Antisoma, Ealing, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antisoma, Ealing, United Kingdom","institution_ids":[]}]},{"author_position":"last","author":{"id":null,"display_name":"Colin Green","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Colin Green","raw_affiliation_strings":["Antisoma, Ealing, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Antisoma, Ealing, United Kingdom","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.3873,"has_fulltext":false,"cited_by_count":5,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.51008181,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":93},"biblio":{"volume":"67","issue":null,"first_page":"4642","last_page":"4642"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10336","display_name":"Cancer Cells and Metastasis","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/dmxaa","display_name":"DMXAA","score":0.9129999876022339},{"id":"https://openalex.org/keywords/vascular-disrupting-agents","display_name":"vascular disrupting agents","score":0.9819999933242798},{"id":"https://openalex.org/keywords/bevacizumab","display_name":"bevacizumab","score":1.0},{"id":"https://openalex.org/keywords/paclitaxel","display_name":"paclitaxel","score":0.9950000047683716},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9190000295639038},{"id":"https://openalex.org/keywords/lung-cancer-xenografts","display_name":"lung cancer xenografts","score":0.8019999861717224},{"id":"https://openalex.org/keywords/anti-angiogenic-therapy","display_name":"anti-angiogenic therapy","score":0.7429999709129333},{"id":"https://openalex.org/keywords/combination-chemotherapy","display_name":"combination chemotherapy","score":0.6159999966621399},{"id":"https://openalex.org/keywords/synergistic-antitumor-effect","display_name":"synergistic antitumor effect","score":0.8899999856948853},{"id":"https://openalex.org/keywords/tumor-growth-inhibition","display_name":"tumor growth inhibition","score":0.5389999747276306},{"id":"https://openalex.org/keywords/a549-cells","display_name":"A549 cells","score":0.8360000252723694},{"id":"https://openalex.org/keywords/tumor-vasculature-targeting","display_name":"tumor vasculature targeting","score":0.6460000276565552},{"id":"https://openalex.org/keywords/anti-vegf-monoclonal-antibody","display_name":"anti-VEGF monoclonal antibody","score":0.7089999914169312}],"concepts":[{"id":"https://openalex.org/C2777802072","wikidata":"https://www.wikidata.org/wiki/Q413299","display_name":"Bevacizumab","level":3,"score":0.8732417821884155},{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.7875269651412964},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7542353868484497},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.7442569732666016},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.6390191912651062},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.5500426292419434},{"id":"https://openalex.org/C2780110267","wikidata":"https://www.wikidata.org/wiki/Q7843332","display_name":"Triple-negative breast cancer","level":4,"score":0.517959475517273},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5069403648376465},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4881008565425873},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.46808797121047974},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.4631499648094177},{"id":"https://openalex.org/C530470458","wikidata":"https://www.wikidata.org/wiki/Q128581","display_name":"Breast cancer","level":3,"score":0.4477991461753845},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.30134862661361694},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.14188936352729797}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2575189539","doi":null,"is_oa":false,"landing_page_url":"https://cancerres.aacrjournals.org/content/67/9_Supplement/4642","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Cancer Research","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":0.9907000064849854,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2788773988","https://openalex.org/W3011545994","https://openalex.org/W2087720231","https://openalex.org/W2611689931","https://openalex.org/W2396431419","https://openalex.org/W159371865","https://openalex.org/W2141892585","https://openalex.org/W2518818911","https://openalex.org/W1970329613","https://openalex.org/W1975094435"],"abstract_inverted_index":{"4642":[0],"The":[3,247,275,353],"anti-VEGF":[4,418],"monoclonal":[5],"antibody,":[6,419],"bevacizumab,":[7],"has":[8,429],"been":[9],"approved":[10],"for":[11,176,223,373],"use":[12],"alongside":[13],"chemotherapy":[14],"in":[15,61,81,86,132,165,185,230,239,309,346,387,435],"colorectal,":[16],"non-small":[17,87],"cell":[18,88,141],"lung,":[19],"and":[20,79,103,124,143,168,188,198,213,253,318,336,390,421,432],"breast":[21],"cancers,":[22],"highlighting":[23],"the":[24,43,64,97,125,138,191,269,326,347,382,412,417,426],"therapeutic":[25],"value":[26],"of":[27,45,51,101,120,250,268,339],"combining":[28,96],"anti-angiogenic":[29],"therapies":[30],"with":[31,77,122,137,159,370,394],"cytotoxic":[32,126],"drugs.":[33],"Vascular":[34],"disrupting":[35],"agents":[36,270],"(VDAs)":[37],"are":[38,57],"a":[39,71,82,104,117,404],"distinct":[40],"approach":[41],"to":[42,115,145,147,262,264,286,314,358],"targeting":[44,408],"tumor":[46,53,221,257,273,295,310,359,422],"vasculature":[47,410],"based":[48],"on":[49,209,294],"disruption":[50],"established":[52,131,409],"blood":[54],"vessels.":[55],"VDAs":[56],"also":[58],"most":[59],"effective":[60],"combination":[62,119,193,249,276,328,354,384],"settings:":[63],"small-molecule":[65],"VDA":[66,105],"DMXAA":[67,121,160,300,374,378],"(AS1404)":[68],"recently":[69],"produced":[70,255,303,329],"substantial":[72],"survival":[73],"benefit":[74],"when":[75],"combined":[76],"carboplatin":[78],"paclitaxel":[80,180,254,380],"phase":[83],"II":[84],"trial":[85],"lung":[89],"cancer.":[90],"We":[91,110],"have":[92,401],"previously":[93],"shown":[94,402],"that":[95,403],"two":[98],"anti-vascular":[99],"approaches":[100],"anti-angiogenesis":[102],"produces":[106],"synergistic":[107],"anti-cancer":[108],"effects.":[109],"now":[111],"extend":[112],"these":[113],"studies":[114],"evaluate":[116],"triple":[118,192,248,327,383,405],"bevacizumab":[123,171,252,298,376],"paclitaxel.":[127],"Xenografts":[129],"were":[130,157,206,211,215,343],"nude":[133],"mice":[134,205],"following":[135],"inoculation":[136],"A549":[139],"(NSCLC)":[140],"line":[142],"allowed":[144],"grow":[146],"approximately":[148],"100":[149],"mm":[150],"3":[151,281],".":[152],"Mice":[153],"(11":[154],"per":[155],"group)":[156],"treated":[158],"(21":[161,194],"mg/kg":[162,182,197,200],"twice":[163,174,183],"weekly":[164,175,184],"weeks":[166,186],"1":[167,187],"4)":[169,189],"or":[170,179,190,241,299,350,377],"(5":[172,181],"mg/kg,":[173,195],"4":[177,333,337],"weeks)":[178],"5":[196,199],"given":[201],"as":[202,217],"above).":[203],"Control":[204],"untreated.":[207],"Effects":[208],"growth":[210,283,311],"measured":[212],"outcomes":[214],"classed":[216],"complete":[218,331],"responses":[219,227,335,345],"(no":[220],"detected":[222],"2":[224,233,330],"weeks);":[225,234],"partial":[226,334],"(>50%":[228,237],"reduction":[229],"volume":[231],"over":[232],"progressive":[235],"disease":[236,243],"increase":[238],"volume)":[240],"stable":[242,340],"(all":[244],"others).":[245],"DMXAA,":[251],"sustained":[256],"regression":[258],"(71-day":[259],"median":[260],"time":[261,357],"return":[263],"baseline":[265],"volume).":[266],"None":[267],"alone":[271,290,301],"caused":[272],"regression.":[274],"group":[277],"showed":[278],"more":[279],"than":[280],"months9":[282],"delay":[284],"compared":[285,313,369],"untreated":[287,315,351,365],"controls.":[288,366],"Paclitaxel":[289],"had":[291],"no":[292,344],"effect":[293],"growth,":[296],"while":[297],"each":[302],"modest":[304],"but":[305],"statistically":[306],"significant":[307,430],"reductions":[308],"rate":[312],"controls":[316],"(26":[317],"35-day":[319],"delays,":[320],"respectively).":[321],"In":[323,398],"outcome":[324],"terms,":[325],"responses,":[332],"cases":[338],"disease.":[341],"There":[342],"single":[348],"agent":[349],"groups.":[352],"regimen":[355],"increased":[356],"progression":[360],"by":[361],"78":[362],"days":[363],"vs":[364],"When":[368],"previous":[371],"data":[372],"plus":[375,379],"combinations,":[381],"was":[385,391],"superior":[386],"all":[388],"respects":[389],"not":[392],"associated":[393],"greater":[395],"toxicity.":[396],"conclusion,":[399],"we":[400],"therapy":[406],"regime":[407],"(with":[411,416,425],"VDA,":[413],"DMXAA),":[414],"neovasculature":[415],"bevacizumab)":[420],"cells":[423],"directly":[424],"cytotoxic,":[427],"paclitaxel)":[428],"promise":[431],"warrants":[433],"evaluation":[434],"clinical":[436],"trials.":[437]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2575189539","counts_by_year":[{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-21T10:27:49.728292","created_date":"2017-01-26T00:00:00"}
